2015

Home/Tag: 2015

Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China

JERUSALEM, December 29, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, today announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Technologies Co. Ltd. ("HTIT"). Oramed has sold 1,155,367 restricted shares [...]

2018-05-30T17:04:16+00:00Categories: Press Releases|Tags: |

Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China

Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share JERUSALEM, Nov. 30, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it [...]

2018-05-30T17:04:16+00:00Categories: Press Releases|Tags: |

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, October 1, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place October 7-9, 2015 in Las [...]

2018-05-30T17:04:16+00:00Categories: Press Releases|Tags: |

Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study

180 Patients Expected to be Enrolled in Study JERUSALEM, September 9, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that 98 patients have already been enrolled in the Company's [...]

2018-05-30T17:04:17+00:00Categories: Press Releases|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, September 4, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 17th Annual Global Investment Conference, taking place [...]

2018-05-30T17:04:17+00:00Categories: Press Releases|Tags: |

Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China

JERUSALEM, July 7, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has signed a non-binding Letter of Intent (LoI) for an investment and license agreement in China [...]

2018-05-30T17:04:19+00:00Categories: Press Releases|Tags: |

Oramed Granted Patent in Russia for Oral Administration of GLP-1

JERUSALEM, June 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, announced today that the Russian Federal Service for Intellectual Property has granted the Company a patent for its invention, titled "Methods and Compositions for Oral Administrations [...]

2018-05-30T17:04:20+00:00Categories: Press Releases|Tags: |